KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EBIT (2016 - 2026)

Idexx Laboratories has reported EBIT over the past 17 years, most recently at $315.6 million for Q4 2025.

  • For Q4 2025, EBIT rose 20.6% year-over-year to $315.6 million; the TTM value through Dec 2025 reached $1.4 billion, up 20.53%, while the annual FY2025 figure was $1.4 billion, 20.53% up from the prior year.
  • EBIT for Q4 2025 was $315.6 million at Idexx Laboratories, down from $354.8 million in the prior quarter.
  • Over five years, EBIT peaked at $373.0 million in Q2 2025 and troughed at $179.1 million in Q2 2022.
  • A 5-year average of $270.8 million and a median of $262.7 million in 2024 define the central range for EBIT.
  • Biggest five-year swings in EBIT: soared 71.57% in 2021 and later tumbled 30.93% in 2022.
  • Year by year, EBIT stood at $199.2 million in 2021, then grew by 13.72% to $226.5 million in 2022, then rose by 8.29% to $245.3 million in 2023, then rose by 6.68% to $261.7 million in 2024, then increased by 20.6% to $315.6 million in 2025.
  • Business Quant data shows EBIT for IDXX at $315.6 million in Q4 2025, $354.8 million in Q3 2025, and $373.0 million in Q2 2025.